Lattice Biologics Ltd. is an e merging leader in personalized medicine, cellular therapies, and tissue engineering, with a focus on bone, skin, and cartilage regeneration. 
The FUTURE of cancer treatment
On  March 30, 2016 , we announced Lattice Biologics commenced its  revolutionary new cancer screening study utilizing regenerative medicine technologies to deliver personalized diagnostics for individuals based on their own cancer tumor cells.  This new process is credited with: 
  • Demonstrating never-before-seen reliability and 
  • Moving the war on cancer from the body to the laboratory, thus protecting patients from suffering the ill effects of unnecessary chemotherapy.
The study is made possible by our exclusive LatBioGel , a revolutionary product powered by Lattice Biologics' proprietary extracellular matrix (ECM) technology.  LatBioGel's innovation lies in  its ability to accurately recreate complex tumor microenvironments.  This allows us to study cancers more effectively.  

We can now grow patients' own cancer tumor cells in a smart, more realistic environment.

We subject patients' t umors to multiple anticancer drugs to determine which treatments are most effective for each patient.   Lattice utilizes h igh content screening methods to analyze up to 10,000 anticancer drug permutations for each patient's cancer cells in just 24 hours. 

Approximately 39% of all people will be diagnosed with cancer at some point during their lifetime. 

The driving goal behind our technology is to eliminate uncertainty from the cancer treatment process and give every patient the absolute best tools to succeed.

Join Lattice at the Society for NeuroOncology 2016 Annual Meeting
Learn more about this technology at the biggest NeuroOncology event of the year in our backyard next week!

Come meet Lattice Biologics' Product Development Direction, Christopher Bradley, Ph.D., who will be sharing our poster presentation, "A Novel Platform for Engineering the Tumor 3D Microenvironment" (by Liudmila Zakharova, Sara D'Imperio, Guy S. Cook, and Christopher A. Bradley).

November 17 - 20, 2016 - Scottsdale Fairmont Princess Hotel 
To view a copy of the preliminary program, CLICK HERE.